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Abstract
Objectives
To assess whether it is feasible to quantify acute change in temporal lobe volume and total
oedema volumes in herpes simplex virus (HSV) encephalitis as a preliminary to a trial of cor-
ticosteroid therapy.
Methods
The study analysed serially acquired magnetic resonance images (MRI), of patients with
acute HSV encephalitis who had neuroimaging repeated within four weeks of the first scan.
We performed volumetric measurements of the left and right temporal lobes and of cerebral
oedema visible on T2 weighted Fluid Attenuated Inversion Recovery (FLAIR) images using
stereology in conjunction with point counting.
Results
Temporal lobe volumes increased on average by 1.6% (standard deviation (SD 11%) in five
patients who had not received corticosteroid therapy and decreased in two patients who had
received corticosteroids by 8.5%. FLAIR hyperintensity volumes increased by 9% in patients
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not receiving treatment with corticosteroids and decreased by 29% in the two patients that
had received corticosteroids.
Conclusions
This study has shown it is feasible to quantify acute change in temporal lobe and total
oedema volumes in HSV encephalitis and suggests a potential resolution of swelling in
response to corticosteroid therapy. These techniques could be used as part of a randomized
control trial to investigate the efficacy of corticosteroids for treating HSV encephalitis in con-
junction with assessing clinical outcomes and could be of potential value in helping to predict
the clinical outcomes of patients with HSV encephalitis.
Introduction
Herpes simplex virus (HSV) encephalitis is the most common infectious cause of sporadic
encephalitis [1–4]. It leads to haemorrhage, necrosis and extensive oedema, characteristically
of the medial temporal lobes, and also additionally extends to affect other limbic areas includ-
ing insular, cingulate and inferolateral frontal cortices [5]. These changes are best visualized by
use of Magnetic Resonance Imaging (MRI) [6]. Although a rare disease with incidence rates of
1 per 250–500,000 [7], the impact of HSV is disproportionately large with huge socioeconomic
demands on patients, their carers and the health services [8–9].
HSV encephalitis is currently treated with the antiviral drug aciclovir. Treatment with aci-
clovir has been reported to improve mortality from 70% to approximately 10–20% [7, 10–11].
However, survivors are left with a variety of sequelae including personality and behavioural
changes, seizures, dysphasia and neuropsychological sequelae including memory problems
[12–13].
Aciclovir stops viral replication but there is growing evidence that ongoing acute brain
inflammation and swelling are major contributing factors to the pathogenesis of HSV en-
cephalitis and may be related to poor outcome [14]. Corticosteroids are used to treat other
neurological infections, including meningitis due to pneumococcus or tuberculosis [15–16].
Adjuvant corticosteroid therapy with aciclovir, in HSV encephalitis, was associated with
improved clinical outcome at three months in a retrospective cohort study [17–18] and a
reduction in severity of MRI abnormalities MRI in a mouse model [19].
In this preliminary study we sought to quantitatively examine serial MRI scans of people
who have had HSV encephalitis to investigate changes in acute brain swelling over time, and
potential resolution of swelling in response to corticosteroid therapy.
Methods
Participants
We performed a retrospective review of adult cases of HSV encephalitis from the ENCE-
PH-UK retrospective cohort study. The ENCEPH-UK study is an NIHR funded programme
grant for applied research to better understand encephalitis and try to improve outcomes.
Details of the programme can be found at www.encephuk.org. The retrospective arm of this
programme builds on the UK Health Protection Agency (now called Public Health England)
Aetiology of Encephalitis in England study [1]. In this study patients with encephalitis were
recruited over a two year period from 2005 to 2007. Potential cases of encephalitis were identi-
fied from 24 hospitals across three regions in England. Patients with acute or sub-acute
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alteration in consciousness, cognition, personality or behaviour changes for more than 24
hours along with any two of: fever, prodromal illness, new onset seizures, focal neurological
signs, pleocytosis (cerebrospinal fluid (CSF) white cell count of> 4 cells/μl), neuroimaging
compatible with encephalitis or electroencephalogram (EEG) compatible with encephalitis, or
any clinical suspicion of encephalitis when the investigations above have not been completed,
were eligible. By using the same inclusion criteria further patients have been recruited to the
retrospective cohort from 17 of the 33 participating sites in the prospective cohort, whose HSV
encephalitis occurred between 2005 and 2013. The study protocols were approved by partici-
pating sites and the National Research Ethics Service (now part of the Health Research Author-
ity) East Midlands Nottingham 1 committee and written consent for entry into the study was
obtained from patients or an accompanying relative. Standardized case record forms for epide-
miological, clinical, demographic, laboratory and radiological data are being used to collect
data. Those meeting the case definitions for HSV encephalitis were included in this study,
namely meeting the suspected encephalitis criteria above along with evidence of inflammation
of brain parenchyma, and no alternative diagnosis made, and HSV type 1 identified by poly-
merase chain reaction (PCR) in the CSF.
MRI Acquisitions
In order to be included in this study, each patient required a coronally-acquired T2- weighted
Fluid Attenuated Inversion Recovery (FLAIR) scan that covered the entire brain. All MRI
scanners had a 1.5 T field strength but the manufacturer and exact acquisition parameters for
each FLAIR image varied but were similar at each site.Details of the scan parameters are in
Table 1 and all scans were suitable for quantitative image analyses using the same stereological
procedure. All scans were acquired as part of the routine clinical care of patients. Patients eligi-
ble for this study had to have had at least two MRI scans performed within four weeks of the
admission scan on the assumption that MRI changes later than this may represent permanent
damage and therefore not amenable to corticosteroid therapy. Each image was viewed care-
fully in terms of quality and potential presence of artefact and a judgement was made as to
whether temporal lobe boundaries could be clearly seen. This assessment was performed by
Table 1. Details of the scan parameters for each patient.
Subject MRI manufacturer Scan TE (ms) TI (ms) TR (ms) Num slices Voxel dimensions (mm)
x y z
1 GE Signa Excite 1.5T 1 111 1743 6975 28 0.47 0.47 4.0
2 111 1743 6975 28 0.47 0.47 4.0
2 GE Signa Excite 1.5T 1 111 1743 6975 28 0.47 0.47 4.0
2 111 1743 6975 28 0.47 0.47 4.0
3 Philips Achieva 1.5T 1 140 2800 11000 26 0.45 0.45 5.0
2 140 2800 11000 26 0.45 0.45 5.0
3 140 2800 11000 26 0.45 0.45 5.0
4 GE Discovery MR450 1.5T 1 128 2300 12000 25 0.43 0.43 5.0
2 140 2800 11000 26 0.45 0.45 5.0
5 GE Genesis Signa 1.5T 1 161 2473 9897 26 0.94 0.94 5.0
2 161 2473 9897 26 0.94 0.94 5.0
6 GE Genesis Signa 1.5T 1 161 2473 9897 28 0.47 0.47 5.0
2 161 2473 9897 28 0.94 0.94 5.0
Legend: TE = echo time. TI = inversion time. TR = repetitions time. Num = number.
doi:10.1371/journal.pone.0170215.t001
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two members of the team. If the boundaries were not clearly seen then the scan was not
included in the analysis.
MRI Analysis
We performed volumetric measurements of the left and right temporal lobe, and of the volume
of cerebral oedema visible on FLAIR images. Although both temporal lobes are frequently
affected by HSV encephalitis often one is more affected than the other. FLAIR image hyperin-
tensities were considered as likely oedema in this study. The volume estimates were obtained
using the Cavalieri method of modern design-based stereology in conjunction with point
counting.This is a mathematically unbiased and reproducible technique for volume estimation
of brain compartments on MR images with high precision [20–22]. Stereological techniques
require a rater to determine the number of test points that intersect a particular region-of-
interest when an array of probes is overlaid onto the MR image. Stereological analysis was per-
formed using Easymeasure software, as previously applied in other stereological studies of
compartmental brain volumes [22–24]. Investigator one had recent training in stereology and
performed the measurements without knowledge of time-point or treatment. Temporal lobe
volume was estimated on the coronal FLAIR images using the same anatomical definitions as
previously described [25–26]. The anterior limit of the temporal lobes was where the temporal
pole disappeared prior to the orbits appearing, and the posterior limit was the coronal section
where the lateral ventricle split into the temporal and frontal horns (approximately the same
section on which the full profile of the crus of the fornix can be visualised) see Fig 1. To obtain
a precise estimate of temporal lobe volume, stereological parameters (i.e., size of test probes,
number of sections, etc.) were optimized to achieve a Coefficient of Error (CE) lower than 5%.
CE is defined as the ratio of the square root of the variance of the volume estimator to its mean
and provides information on the precision of each volume estimate and is dependent on the
complexity and size of a structure. Detailed information on the estimation of the CE is pro-
vided elsewhere [22, 27]. Separation between test points on the square grid used for point
counting was 7 pixels with slice intervals between 4.0 and 5.0mm (i.e. every MR section,).
Temporal lobe transect area was obtained by multiplying the total number of points recorded
by the area corresponding to each test point. An estimate of temporal lobe volume was
Fig 1. Image using the easymeasure stereology, point counting software showing the landmarks for temporal lobe measurements. (1) where the
lateral ventricle splits into the temporal and frontal horns as the posterior limit for the right temporal lobe in a HSV encephalitis patient; (2) the mid point of the
right temporal lobe measurement (in yellow the previously calculated left temporal lobe calculation); (3) the anterior limit of the temporal lobe and (4) the mid
point section in (2) showing the volume of the overall damage including that outwith the temporal lobe, where HSV is seen to affect the right temporal lobe on
this slice.
doi:10.1371/journal.pone.0170215.g001
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obtained as the sum of the estimated areas of the structure transects on consecutive systematic
sections multiplied by the distance between sections. Approximately 600 points were recorded
on approximately 24 systematic random sections through the temporal lobe. All measurements
were repeated by the first investigator in order to calculate intra-rater variability. For the pur-
pose of calculating inter-rater variability, a second investigator, with 17 years-experience of
imaging stereology, completed volume measurements of the temporal lobe in both hemispheres
and the extent of oedema overall in all six cases without knowledge of time point or treatment.
Given that in HSVE brain damage is not always limited to the temporal lobes, the total vol-
ume of signal abnormality on T2-weighted FLAIR images, loosely defined as cerebral oedema,
was also measured for each hemisphere of the brain using the same stereological approach and
software described for the temporal lobe (see Fig 1 image d). Separation between test points on
the square grid used for point counting was 10 pixels, and slice interval was between 4 and 5 mm
(every MR section). The region of interest was based on the area of FLAIR image hyperintensity.
All hyperintense FLAIR image voxels were classified as being oedema and as previously observed
for the pattern of HSV encephalitis, were in the temporal and limbic regions. All images for
FLAIR assessment were reviewed with a neuroradiologist blinded to clinical information.
Statistical analysis: All statistical analysis was carried out using the SAS statistical package
(Version9.3). Intra- and inter-examiner reliability were assessed using intraclass correlation
coefficients.
Results
There were ten patients who had at least one repeat MRI within 4 weeks of the admission scan.
Of these, four could not be analysed: three patients did not have coronal T2-weighted FLAIR
scans performed on both sets of scans and one patient had poor quality images on the follow
up T2-weighted FLAIR scan (Fig 2).
Patients were recruited initially on the basis of suspicion of encephalitis and subsequently
confirmed as proven HSV-type 1 encephalitis on the grounds of evidence of inflammation on
either cerebrospinal fluid (CSF) assessment, electroencephalogram (EEG) or Magnetic Reso-
nance Imaging (MRI) findings. HSV type 1 was proven by polymerase chain reaction (PCR) in
the CSF.
For the remaining six patients, two patients received corticosteroid therapy during their
admission. One of these patients (Patient 3), had three MRI scans, thus enabling the 1st period
to be assessed as change in neuroimaging without corticosteroid therapy and the 2nd interval
as the change in neuroimaging post corticosteroid therapy. The demographics of the patients
are described in Table 2.
All patients experienced headache on admission but none had any other meningitic symp-
toms. All but one patient experienced fever on admission. The patient (Patient 2) that did not
experience fever had been experiencing olfactory hallucinations prior to admission for many
days, though a seizure triggered the admission to hospital. Olfactory hallucinations were also
experienced by Patient 2. Focal neurology and expressive dysphasia was experienced in three
and four patients respectively. None of the patients were immunocompromised on admission.
Although lumbar punctures (LPs) were performed in all patients, two did not have an opening
pressure recorded. For the others the initial opening pressure was either at the top end of nor-
mal or elevated and on subsequent LPs had reduced. CTs were available for all but one patient
and reports described extensive swelling or swollen cortices suggestive of oedema. Patient 1
received a total of 17mg of intravenous dexamethsone over 6 days, commencing on day 6 of
the admission and Patient 3 received a total of 316mg of intravenous dexamethasone over 19
days starting on day 4 of the admission.
Magnetic Resonance Imaging Herpes Simplex Encephalitis
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Fig 2. Flow chart of inclusion of patients in this study.
doi:10.1371/journal.pone.0170215.g002
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Intra-rater variability, as measured by intraclass correlation coefficient (ICC), for temporal
lobe and total oedema volume measurements was 0.998 and 0.995 respectively. The ICC for
inter-rater variability for temporal lobe measurements was 0.976 and for total oedema mea-
surements was 0.876.
Quantitative longitudinal analysis revealed that temporal lobe volume increased on average
by 1.6% (standard deviation (SD 11%) in five patients who had not received corticosteroid
therapy and decreased in two patients who had received corticosteroids by 8.5% (SD 0.5%).
Furthermore, quantitative analyses of changes in FLAIR hyperintensity volumes were
found to increase on average by 9% (SD 15.1%) in patients not receiving treatment with corti-
costeroids and decreased on average by 29% (SD 1.5%) in the two patients that had received
corticosteroids. These findings are tabulated in Table 3.
The individual volume changes for each patient are presented in Table 4, Fig 3 and Fig 4.
Fig 5. illustrates the changes for the patient who had three MRI scans showing the increase
before corticosteroid therapy and the subsequent decrease after therapy.
The outcomes for the patients, in terms of length of stay, discharge Glasgow outcome score,
where they were discharged to and their general health status at one year as measured by the
SF36 are reported in Table 2.
Discussion
In this small study of HSV encephalitis most patients on standard therapy had an increase in
temporal lobe volume (three out of five) and of overall FLAIR-identified oedema (four out of
five) during their acute hospital admission. However, a decrease in temporal lobe and oedema
Table 2. Characteristics of the patients on admission and their outcomes up to one year post discharge.
Patient Age
(yrs)
Sex Symptom duration
before admission
(days)
Symptom
triggering
admission
GCS
o/a
Delayed
aciclovir
(>48hrs)
Steroid
therapy
ICU
stay
LOS
(days)
Discharge
GOS
Discharge
location
SF36 at
1 year
1 53 F 4 Seizure 9 Y YES Y 78 3 Rehab Poor
2 19 F 28a Seizure 15 N NO N 21 5 Home Good
3 41 F 3 Focal neurology 14 N YES N 31 4 Home Good
4 52 F 4 Headache 14 N NO Y 44 4 Home Good
5 54 M 8 Coma 5 N NO N 34 5 Home Fair
6 45 M 1 Seizure 3 Y NO Y 82 3 Rehab Poor
Legend: yrs = years, M = male and F = female; GCS = Glasgow coma scale, a scale of consciousness from 3 to 15; o/a = on admission; ICU = intensive
care unit; LOS = length of stay; GOS = Glasgow outcome score where 1 is dead and 5 is back to normal; SF36 = short form 36; a measure of general health
status; Y = yes and N = no.
a olfactory hallucinations occurred for 28 days prior to a seizure prompting admission
doi:10.1371/journal.pone.0170215.t002
Table 3. A 2x2 table demonstrating whether volume changes increased or decreased in the two
groups of patients, those treated with corticosteroids and those that were not.
Volume measurement Treated group (2) Not treated group (5)
Temporal lobes
Increase 0 3
Decrease 2 2
Total FLAIR
Increase 0 4
Decrease 2 1
doi:10.1371/journal.pone.0170215.t003
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volume was observed in both patients who received corticosteroid therapy. Although the num-
bers are small in this study, the difference in the total oedema volumes between the patients
not treated with corticosteroids and those that were, appears interesting and warrants further
study
HSV encephalitis is a rare condition but its impact is considerable, including long hospital
admissions, neurocognitive sequelae and prolonged periods off work. In one series only 14%
of patients were reported as having complete recovery at six months by the Glasgow Outcome
Score and in another study 45% of survivors who were in employment prior to their illness
Table 4. Magnetic resonance imaging abnormalities found and volume changes for each individual patients.
Patient Time to 1st scan
from symptom
onset (days)
Time to 1st MRI
from admission
(days)
Time b/n
MRI scans
(days)
Abnormality on coronal T2w FLAIR Steroid
therapyUnilateral or
Bilateral TL
damage
Damage
confined to
TL
Proportionate volume
change of worst
affected TL
Volume change of
oedematous
region
1 5 1 6 Bilateral No 0.92 0.70 Yes
2 29 1 6 Unilateral No 0.94 1.02 No
3a 6 3 4 Bilateral No 1.04 1.28 No
3b Na NA 14a Bilateral No 0.91 0.73 Yes
4 6 2 27 Bilateral No 0.90 0.85 No
5 14 6 11 Unilateral No 1.02 1.08 No
6 2 1 34 Bilateral No 1.18 1.27 No
Legend: TL = temporal lobe, MRI = magnetic resonance imaging, FLAIR = fluid attenuation inversion recovery; b/n = between. Patient 3a and 3b are the
same person, 3a pre corticosteroid therapy and 3b post corticosteroid therapy, LOS length of stay. 3a is the period before corticosteroids, and 3b the period
after corticosteroids were administered for patient 3.
a this is the duration between the 2nd and 3rd scans.
doi:10.1371/journal.pone.0170215.t004
Fig 3. Change in volume of most affected temporal lobe over time. Patients 1 and 3 received corticosteroids during their care in hospital.
doi:10.1371/journal.pone.0170215.g003
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were unemployed at three years after their acute illness, [8–9]. Estimations of hospital stay
costs in patients with encephalitis in the United States have shown a hospital admission in
2010 due to HSV encephalitis cost an average of $58,082 with total encephalitis associated hos-
pitalisations amounting to approximately $2 billion [28]. In our series 33% were reported as
having had a complete recovery at discharge and 50% having good outcomes at one year.
Previous neuroimaging studies in encephalitis have been mainly descriptive or correlate
areas of abnormalities with clinical states or with aetiologies. In one study, initial abnormal CT
scans, within three days of admission, was identified as a poor prognostic factor whilst another
study identified ‘extensive’ MRI changes as being associated with poorer outcomes in HSV
encephalitis [29–30]. Another study retrospectively examined MRI scans of patients with
encephalitis and temporal lobe abnormalities suggesting that it is advantageous for predicting
the aetiology to know whether abnormalities are located solely within one temporal lobe or are
bilateral [31].
Verbal memory is particularly affected in patients that survive HSV encephalitis, which
most likely reflects the fact that the damage is predominantly in the temporal lobes where new
memories are formed [12–13, 32–34]. Bilateral temporal lobe swelling on MRI was associated
Fig 4. Change in volume of total oedema over time. Patients 1 and 3 received corticosteroids during their care in hospital.
doi:10.1371/journal.pone.0170215.g004
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with the severity of neuropsychological sequelae and in particular memory impairment [35].
In future larger studies, it will be important, therefore, to assess cognitive sequelae in conjunc-
tion with temporal lobe damage.
Few studies have quantified brain abnormalities in HSV encephalitis and fewer still have
correlated these with clinical information. Some studies have performed correlations between
different modalities of neuroimaging, for example between FLAIR images and Diffusion
Weighted Imaging (DWI), and others have used voxel based morphometry to correlate with
neurocognitive problems on research scans not typically acquired in routine clinical practice
[36–37].
We found that our inter-rater correlation was better for temporal lobe measurements com-
pared to total oedema volume measurements most likely because of the subjectivity associated
with assessing areas of diffuse hyperintensity. Temporal lobe measurements have been stan-
dardized previously and HSV encephalitis is well known to cause damage in the temporal
lobes. However, HSV commonly affects extra-temporal lobe regions and bihemispheric alter-
ations are frequently observed. Measurement of temporal lobe volumes alone therefore would
neglect significant areas of abnormality in HSV encephalitis. This was highlighted in the pres-
ent study were larger changes in volumes were observed over time when assessing the whole
area affected by HSV encephalitis and not solely the most affected temporal lobe. Indeed, in
the two patients who received corticosteroids the decrease in temporal lobe volume was 8.5%.
However, the decrease in volume of the area of oedema was 29% when the whole area of
FLAIR hyperintensity was examined. From the data presented here there is a suggestion that
corticosteroids can reduce damage caused by HSV encephalitis as viewed on MRI in the acute
period of admission.
There are a number of limitations of this study. In particular it is retrospective, the numbers
are small with limited ability to draw clinical correlations and the corticosteroids were not
randomly administered. Indeed, the most clinically impaired patients may be those that
get repeated neuroimaging or receive corticosteroids. Existing national and international
guidelines do not suggest repeat neuroimaging in HSV encephalitis nor are corticosteroids
Fig 5. Coronal T2-weighted FLAIR images of a 45 year old woman with HSV encephalitis (Patient 3). On day 7 of admission a five-day course of
corticosteroids was started. The same image slice is depicted from the day 2 scan (Image 1), from day 6 (Image 2) and from day 21 (Image 3)
doi:10.1371/journal.pone.0170215.g005
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recommended [38–39]. Therefore, the majority of patients with HSV encephalitis do not get
either. Thus the use of three sets of MRI scans including before and after corticosteroid therapy
was opportunistic in this feasibility study for both the treatment group and non-treatment
group. Furthermore, MRIs were not standardised in this study as they were acquired in the
context of a routine clinical setting. Also the surrogate marker of T2-weighted FLAIR imaging
was used as an indication of oedema caused by HSV infection, but it is possible that the regions
of hyperintesity were due to other underlying pathology such as haemorrhage. Furthermore,
in the case of oedema, T2-weighted FLAIR alone cannot evaluate whether this is due to cyto-
toxic or vasogenic oedema. The use of additional MRI modalities, particularly DWI, would be
important to further evaluate this. Although it is unorthodox to use the same participant for
both a non-treatment group and a treatment group, this was a feasibility study for the stereol-
ogy technique.
This was an opportunistic study of neuroimaging performed in routine clinical practice in
HSV encephalitis. Furthermore each patient had their scans performed on the same scanner
with the same scan parameters and therefore this should not affect serial intra-patient results.
Clinical outcomes should be evaluated in any future study both on the predictive value of
neuroimaging on clinical manifestations in general, and in particular neuropsychological out-
comes. In terms of the effectiveness of corticosteroids both on neuroimaging and also impor-
tantly on clinical outcomes, a randomized control trial would be necessary and to date none
have been performed. Certainly the need for such a trial was identified in a systematic review
in 2006 [40].
The randomised control trial, DexEnceph, which has opened to recruitment in January
2016, aims to answer the question of whether corticosteroids are beneficial and safe in treating
HSV encephalitis. The trial will determine whether dexamethasone improves neuropsycholog-
ical outcomes in sufferers of HSV encephalitis without allowing uncontrolled viral replication
and whether corticosteroids will improve the neuroimaging, functional and quality of life out-
comes. These developments are in turn likely to lead to obtaining a better understanding of
the disease mechanisms in HSV encephalitis.
The findings from this study have shown that it is feasible to use routine clinical scans to
evaluate and quantify the area of damage by HSV encephalitis and in the context of a larger
randomized controlled trial could be valuable for the investigation of encephalitis and help
predict clinical outcomes thus potentially enhancing the existing national guidelines on the
management of HSV encephalitis.
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